These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8303756)

  • 1. Tissue-type plasminogen activator improves neurological functions in a rat model of thromboembolic stroke.
    Sakurama T; Kitamura R; Kaneko M
    Stroke; 1994 Feb; 25(2):451-6. PubMed ID: 8303756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intra-arterial tissue plasminogen activator and urokinase on autologous arterial emboli in the cerebral circulation of rabbits [corrected].
    Benes V; Zabramski JM; Boston M; Puca A; Spetzler RF
    Stroke; 1990 Nov; 21(11):1594-9. PubMed ID: 2122553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats.
    Sereghy T; Overgaard K; Boysen G
    Stroke; 1993 Nov; 24(11):1702-8. PubMed ID: 8236347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia.
    Zhang L; Zhang ZG; Zhang RL; Lu M; Adams J; Elliott PJ; Chopp M
    Stroke; 2001 Dec; 32(12):2926-31. PubMed ID: 11739997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
    del Zoppo GJ; Higashida RT; Furlan AJ; Pessin MS; Rowley HA; Gent M
    Stroke; 1998 Jan; 29(1):4-11. PubMed ID: 9445320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke.
    Papadopoulos SM; Chandler WF; Salamat MS; Topol EJ; Sackellares JC
    J Neurosurg; 1987 Sep; 67(3):394-8. PubMed ID: 3112328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic treatment of clot embolism in rat: comparison of intra-arterial and intravenous application of recombinant tissue plasminogen activator.
    Niessen F; Hilger T; Hoehn M; Hossmann KA
    Stroke; 2002 Dec; 33(12):2999-3005. PubMed ID: 12468803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic efficacy of a modified tissue-type plasminogen activator, SUN9216, in the rat middle cerebral artery thrombosis model.
    Umemura K; Toshima Y; Nakashima M
    Eur J Pharmacol; 1994 Sep; 262(1-2):27-31. PubMed ID: 7813575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
    Niessen F; Hilger T; Hoehn M; Hossmann KA
    Stroke; 2003 Aug; 34(8):2019-24. PubMed ID: 12843350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of human recombinant prourokinase(rhpro-UK) on thromboembolic stroke in rats.
    Hao CH; Ding WX; Sun Q; Li XX; Wang WT; Zhao ZY; Tang LD
    Eur J Pharmacol; 2018 Jan; 818():429-434. PubMed ID: 29154937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat.
    Jiang Q; Zhang RL; Zhang ZG; Ewing JR; Divine GW; Chopp M
    J Cereb Blood Flow Metab; 1998 Jul; 18(7):758-67. PubMed ID: 9663506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits.
    Lyden PD; Zivin JA; Clark WA; Madden K; Sasse KC; Mazzarella VA; Terry RD; Press GA
    Neurology; 1989 May; 39(5):703-8. PubMed ID: 2496332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early (1 h) administration of tissue plasminogen activator reduces infarct volume without increasing hemorrhagic transformation after focal cerebral embolization in rats.
    Zhang RL; Chopp M; Zhang ZG; Divine G
    J Neurol Sci; 1998 Sep; 160(1):1-8. PubMed ID: 9804110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-arterial prourokinase for acute ischemic stroke.
    Akins PT
    JAMA; 2000 Apr; 283(16):2102; author reply 2103-4. PubMed ID: 10791495
    [No Abstract]   [Full Text] [Related]  

  • 16. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
    Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
    Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The treatment of cerebrovascular thrombosis and embolism with fibrinolytic agents].
    Araki G
    No To Shinkei; 1992 Sep; 44(9):771-7. PubMed ID: 1476806
    [No Abstract]   [Full Text] [Related]  

  • 19. [Thrombolytic therapy in ischemic infarct].
    Willig V; Steiner T; Hacke W
    Wien Klin Wochenschr; 1997 Oct; 109(20):795-803. PubMed ID: 9454430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
    Lapchak PA; Araujo DM; Song D; Zivin JA
    Stroke; 2002 Jan; 33(1):147-52. PubMed ID: 11779904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.